Vivus (VVUS +0.2%) shares reverse course after suffering heavy losses earlier and hover around zero after USA Today reports that the FDA has approved its Qnexa/Qysemia diet drug. However, no other news organizations appear to have reported the story, and it's not on the FDA website. Update: the linked-story in this MC seems to have been taken down. Vivus shares -0.6%.
Vivus (VVUS +0.2%) shares reverse course after suffering heavy losses earlier and hover around...
From other sites
at CNBC.com (Dec 2, 2014)
at CNBC.com (Dec 1, 2014)
at CNBC.com (Oct 27, 2014)
at CNBC.com (Sep 18, 2014)
at CNBC.com (Sep 11, 2014)
ETF Screener: Search and filter by asset class, strategy, theme, performance, yield, and much more
ETF Performance: View ETF performance across key asset classes and investing themes
ETF Investing Guide: Learn how to build and manage a well-diversified, low cost ETF portfolio
ETF Selector: An explanation of how to select and use ETFs